RADICAL-REACT

  • Research type

    Research Study

  • Full title

    Rapid Absorbance-based Detection of Inner Cheek cell Abnormalities using Light spectroscopy for Risk Evaluation of lung cancer to enable Critical decision support in Targeted patient populations (RADICAL-REACT).

  • IRAS ID

    339509

  • Contact name

    Anoop Chauhan

  • Contact email

    anoop.chauhan@porthosp.nhs.uk

  • Sponsor organisation

    Sierra Medical Ltd

  • Clinicaltrials.gov Identifier

    NCT07051044

  • Duration of Study in the UK

    1 years, 6 months, 1 days

  • Research summary

    Sierra Medical is at the forefront of early detection of Lung Cancer with the creation of AIR-DS, a non-invasive early detection test. This innovative approach aims to significantly enhance the early identification of lung cancer, potentially catching it at its most treatable stages through a simple cheek swab.

    AIR-DS could represent a significant advancement in lung cancer detection, focusing on early, accurate diagnosis through a non-invasive cheek swab. Beyond improving patient outcomes by enabling timely intervention, it also introduces a cost-effective approach to early lung cancer detection. AIR-DS aims to alleviate the financial burden on healthcare systems and patients by reducing the need for more expensive and/or invasive diagnostic procedures.

    The effectiveness of AIR-DS stems from its ability to identify small biochemical changes in cells from the inner cheek. These biochemical changes can serve as early indicators of lung cancer. The procedure involves taking a cheek swab, which is then analysed using non-damaging infrared light technology.

    To introduce this technology into a healthcare setting we need to validate its effectiveness through rigorous testing. The RADICAL REACT trial plans to involve around 450 participants, highly suspected to have lung cancer. Each participant will attend a single visit in a secondary care setting or research clinic to provide a cheek swab, have a lung function test and provide basic medical history information. The data collected will be analysed with AIR-DS to identify whether individuals with lung cancer can be identified accurately.

  • REC name

    London - Stanmore Research Ethics Committee

  • REC reference

    24/LO/0349

  • Date of REC Opinion

    14 May 2024

  • REC opinion

    Favourable Opinion